Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Acquired by Bank of New York Mellon Corp

Bank of New York Mellon Corp increased its holdings in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) by 19.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 331,853 shares of the biopharmaceutical company’s stock after buying an additional 54,150 shares during the period. Bank of New York Mellon Corp owned about 0.68% of Puma Biotechnology worth $1,012,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in PBYI. Gateway Wealth Partners LLC purchased a new position in Puma Biotechnology during the fourth quarter valued at $31,000. Franklin Resources Inc. purchased a new position in Puma Biotechnology in the 3rd quarter valued at about $41,000. Dynamic Technology Lab Private Ltd acquired a new stake in Puma Biotechnology in the 3rd quarter worth about $44,000. Virtu Financial LLC purchased a new stake in Puma Biotechnology during the 3rd quarter worth approximately $68,000. Finally, SG Americas Securities LLC raised its holdings in shares of Puma Biotechnology by 83.9% during the fourth quarter. SG Americas Securities LLC now owns 24,668 shares of the biopharmaceutical company’s stock valued at $75,000 after acquiring an additional 11,252 shares during the last quarter. Institutional investors and hedge funds own 61.29% of the company’s stock.

Insiders Place Their Bets

In other news, insider Jeffrey Jerome Ludwig sold 9,437 shares of Puma Biotechnology stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total transaction of $29,726.55. Following the sale, the insider now owns 108,951 shares of the company’s stock, valued at approximately $343,195.65. The trade was a 7.97 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Alan H. Auerbach sold 33,841 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total value of $106,599.15. Following the completion of the transaction, the chief executive officer now owns 7,029,674 shares in the company, valued at $22,143,473.10. This represents a 0.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 23.70% of the company’s stock.

Puma Biotechnology Stock Down 1.1 %

PBYI stock opened at $3.47 on Tuesday. The company has a market cap of $172.15 million, a price-to-earnings ratio of 7.23 and a beta of 1.33. The firm has a 50-day moving average of $3.09 and a two-hundred day moving average of $2.96. Puma Biotechnology, Inc. has a 12 month low of $2.23 and a 12 month high of $6.06. The company has a current ratio of 1.42, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported $0.39 EPS for the quarter, beating the consensus estimate of $0.10 by $0.29. The firm had revenue of $59.10 million during the quarter, compared to analysts’ expectations of $52.50 million. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. As a group, analysts forecast that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on PBYI. StockNews.com lowered Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Saturday, March 8th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Puma Biotechnology in a research note on Friday, February 28th.

Puma Biotechnology Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.